Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease

17 Aug 2023

Abstract excerpt

Huntington disease (HD) is a neurodegenerative disorder caused by an expanded polyglutamine (CAG) trinucleotide expansion in the huntingtin (HTT) gene that encodes the mutant huntingtin protein (mHTT). Visualization and quantification of cerebral mHTT will provide a proxy for target engagement and a means to evaluate therapeutic interventions aimed at lowering mHTT in the brain. Here, we validated the novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37591545
DOI: 10.2967/jnumed.123.265569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington DiseasePMID 37591545Read ↗

In Vivo PET Imaging of [18F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease.Semantic proximity Read ↗

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s diseaseSemantic proximity Read ↗

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s diseaseSemantic proximity Read ↗

PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.Semantic proximity Read ↗

Preclinical evaluation of [ <sup>11</sup> C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read ↗

Preclinical evaluation of [11C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read ↗

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesSemantic proximity Read ↗

Longitudinal Preclinical Evaluation of the Novel Radioligand [11C]CHDI-626 for PET Imaging of Mutant Huntingtin Aggregates in Huntington’s DiseaseSemantic proximity Read ↗

Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.Semantic proximity Read ↗

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.Semantic proximity Read ↗

Preclinical evaluation of the novel [ <sup>18</sup> F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington’s diseaseSemantic proximity Read ↗

Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.